Shenzhen Chipscreen Biosciences Co Asset Resilience Ratio
Shenzhen Chipscreen Biosciences Co asset resilience ratio. Shenzhen Chipscreen Biosciences Co (688321) has an Asset Resilience Ratio of 5.10% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 688321 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shenzhen Chipscreen Biosciences Co (2016–2024)
Asset resilience ratio of Shenzhen Chipscreen Biosciences Co from 2016 to 2024. This chart shows how Shenzhen Chipscreen Biosciences Co's Asset Resilience Ratio has changed over time. See cash generation quality of Shenzhen Chipscreen Biosciences Co to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Shenzhen Chipscreen Biosciences Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 688321 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥185.25 Million | 5.1% |
| Total Liquid Assets | CN¥185.25 Million | 5.10% |
Asset Resilience Insights
- Limited Liquidity: Shenzhen Chipscreen Biosciences Co maintains only 5.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shenzhen Chipscreen Biosciences Co Industry Peers by Asset Resilience Ratio
Compare Shenzhen Chipscreen Biosciences Co's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Shenzhen Chipscreen Biosciences Co Asset Resilience Ratio by Year (2016–2024)
Shenzhen Chipscreen Biosciences Co asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Shenzhen Chipscreen Biosciences Co.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.90% | CN¥94.13 Million ≈ $13.77 Million |
CN¥3.25 Billion ≈ $475.71 Million |
-3.87pp |
| 2023-12-31 | 6.77% | CN¥216.72 Million ≈ $31.71 Million |
CN¥3.20 Billion ≈ $468.74 Million |
-3.29pp |
| 2022-12-31 | 10.05% | CN¥291.07 Million ≈ $42.59 Million |
CN¥2.90 Billion ≈ $423.75 Million |
+5.72pp |
| 2021-12-31 | 4.33% | CN¥82.08 Million ≈ $12.01 Million |
CN¥1.89 Billion ≈ $277.21 Million |
-10.84pp |
| 2020-12-31 | 15.17% | CN¥261.87 Million ≈ $38.32 Million |
CN¥1.73 Billion ≈ $252.61 Million |
+14.93pp |
| 2019-12-31 | 0.24% | CN¥4.02 Million ≈ $588.49K |
CN¥1.69 Billion ≈ $247.51 Million |
-5.60pp |
| 2018-12-31 | 5.84% | CN¥41.83 Million ≈ $6.12 Million |
CN¥716.34 Million ≈ $104.82 Million |
-19.75pp |
| 2017-12-31 | 25.59% | CN¥167.86 Million ≈ $24.56 Million |
CN¥656.02 Million ≈ $96.00 Million |
+0.41pp |
| 2016-12-31 | 25.18% | CN¥101.49 Million ≈ $14.85 Million |
CN¥403.13 Million ≈ $58.99 Million |
-- |
About Shenzhen Chipscreen Biosciences Co
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research and development of original small molecule drugs. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer; Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases; and Chiauranib, a t… Read more